quality and efficiency of clinical trials.
April 25 - 26, 2012
Hilton Washington DC/Rockville Executive Meeting Center, Rockville, MD
The willingness of institutions to defer full local institutional review board (IRB) review and approval to a central IRB in multicenter trials continues to vary, despite a 2006 U.S. Food and Drug Administration (FDA) guidance and a more recent endorsement by the U.S. Office for Human Research Protections recommending this approach. The goal of the CTTI project is to identify potential solutions to address barriers to the adoption of central IRBs for multicenter clinical trials.
*The views and opinions expressed in this presentation are those of the individual presenter and should not be attributed to the Clinical Trials Transformation Initiative, or any organization with which the presenter is employed or affiliated.
Most Visited Pages
CTTI encourages the use of all materials listed on this site in the pursuit of improving the clinical trials enterprise. Our recomendations, tools, meeting summaries, and more are available to the public for free. We do ask that you acknowledge the source whenever using or referencing CTTI materials. Read our Citation Policy here.